CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 445 enrolled
Drug / intervention
Atomoxetine hydrochloride +1 moredrug
Likely dose
Atomoxetine hydrochloride 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00510276
NCT00510276Phase 4Completed
CompareCT.gov

A Double-Blind Study of Atomoxetine Hydrochloride Versus Placebo for the Treatment of ADHD in Young Adults With an Assessment of Associated Functional Outcomes

Eli Lilly and Company·interventional·Posted Aug 1, 2007·Updated Apr 14, 2010

In Brief

A Phase 4 clinical trial evaluating Atomoxetine hydrochloride and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 445 participants across 29 sites in 2 countries.

Detailed Summary

This study will evaluate atomoxetine's efficacy in treating attention-deficit/hyperactivity disorder (ADHD) symptoms and atomoxetine's effect on functional outcomes in young adults. A gatekeeper strategy will be employed for sequentially testing the secondary objectives. This study also has an observational community sample arm in which patients will complete all the efficacy measurements via web-based self reporting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 1, 2007
Enrollment StartAug 1, 2007
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.9 years ago

Interventions

Atomoxetine hydrochloridedrug

20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks

Placebodrug

twice a day, by mouth for 12 weeks